Clinical trial · Interventional
A Single-center Clinical Study to Evaluate the Safety and Efficacy of Autologous Bone Marrow-derived DCs(CellgramDC-WT1) and Immune Checkpoint Inhibitors in Patients With Metastatic Pancreatic Cancer Who Have Failed First-line or More Standard Chemotherapy
NCT06172634CI-TRIAL-00072313DICI_PCunknownPhase 1 / Phase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To evaluate the safety and effectiveness of immune cell therapy using autologous bone marrow-derived dendritic cells and immune checkpoint inhibitors in patients with metastatic pancreatic cancer who have failed at least one standard anticancer treatment.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreas Cancer | Pancreatic Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| dentritic cell infusion and immunecheckpoint inhibitor | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- DC + ICI
- interventionNames
- Drug: dentritic cell infusion and immunecheckpoint inhibitor
Primary outcomes (1)
- measure
- treatment related adeverse event
- timeFrame
- for 1yr
Secondary outcomes (1)
- measure
- overall response rate
- timeFrame
- for 1yr
- description
- treatment response
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 19 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Patients histologically confirmed to have pancreatic cancer and diagnosed as recurrent or metastatic * Patients whose disease was confirmed to have progressed according to RECIST v1.1 after 1st or more standard anticancer treatments * Patients satisfying systemic performance status ECOG 0-2 * Patients who have not undergone surgery, radiation therapy, or immunotherapy within 4 weeks and have recovered from side effects (However, tissue collection procedures that do not affect the test subject's condition are permitted at the discretion of the researcher.) * Patients who voluntarily agreed in writing to participate in this clinical study Exclusion Criteria: * Patients with malignant tumors other than non-melanoma skin cancer in the past 3 years * Patients who have previously received anti-tumor immunotherapy (anti-PD1, anti-PDL-1, or CTLA4 inhibitor, etc.) or participated in clinical studies related to immunotherapy or cell therapy * Patients with active autoimmune disease requiring systemic immunosuppressive treatment * Patients with a history of organ or hematopoietic stem cell transplantation * Patients with acute or chronic infection requiring systemic treatment * Other cases where the test manager determines that it is not suitable for clinical research
References
Publications (0)
Data not yet available
No reference posted for this study.